Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis

Sonja Falvey, Lauren Shipman, Norman Todd Ilowite, Timothy Beukelman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Methotrexate is the most commonly used disease modifying antirheumatic drug in the treatment of juvenile idiopathic arthritis and can be effective in controlling disease in many patients. Main body: A significant proportion of patients experience nausea and vomiting induced by methotrexate therapy, which can lead to decreased quality of life and discontinuation of treatment with methotrexate. Many strategies have been employed in attempts to reduce methotrexate-induced nausea, including folate supplementation, switching from oral to subcutaneous methotrexate, anti-emetic therapy, behavioral therapy, and others. Anticipatory nausea can be difficult to treat, making primary prevention of nausea with anti-emetics an attractive approach. Conclusion: Understanding the prevalence and impact of methotrexate-induced nausea, as well as potentially effective interventions, may help maximize the therapeutic benefits of methotrexate.

Original languageEnglish (US)
Article number52
JournalPediatric Rheumatology
Volume15
Issue number1
DOIs
StatePublished - Jun 19 2017

Fingerprint

Juvenile Arthritis
Methotrexate
Nausea
Antiemetics
Therapeutics
Antirheumatic Agents
Primary Prevention
Folic Acid
Vomiting
Quality of Life

Keywords

  • JIA
  • Juvenile idiopathic arthritis
  • Methotrexate
  • MTX
  • Nausea
  • Vomiting

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Rheumatology

Cite this

Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis. / Falvey, Sonja; Shipman, Lauren; Ilowite, Norman Todd; Beukelman, Timothy.

In: Pediatric Rheumatology, Vol. 15, No. 1, 52, 19.06.2017.

Research output: Contribution to journalArticle

Falvey, Sonja ; Shipman, Lauren ; Ilowite, Norman Todd ; Beukelman, Timothy. / Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis. In: Pediatric Rheumatology. 2017 ; Vol. 15, No. 1.
@article{727591f6242a445e8db476b66da0b5ca,
title = "Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis",
abstract = "Background: Methotrexate is the most commonly used disease modifying antirheumatic drug in the treatment of juvenile idiopathic arthritis and can be effective in controlling disease in many patients. Main body: A significant proportion of patients experience nausea and vomiting induced by methotrexate therapy, which can lead to decreased quality of life and discontinuation of treatment with methotrexate. Many strategies have been employed in attempts to reduce methotrexate-induced nausea, including folate supplementation, switching from oral to subcutaneous methotrexate, anti-emetic therapy, behavioral therapy, and others. Anticipatory nausea can be difficult to treat, making primary prevention of nausea with anti-emetics an attractive approach. Conclusion: Understanding the prevalence and impact of methotrexate-induced nausea, as well as potentially effective interventions, may help maximize the therapeutic benefits of methotrexate.",
keywords = "JIA, Juvenile idiopathic arthritis, Methotrexate, MTX, Nausea, Vomiting",
author = "Sonja Falvey and Lauren Shipman and Ilowite, {Norman Todd} and Timothy Beukelman",
year = "2017",
month = "6",
day = "19",
doi = "10.1186/s12969-017-0180-2",
language = "English (US)",
volume = "15",
journal = "Pediatric Rheumatology",
issn = "1546-0096",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis

AU - Falvey, Sonja

AU - Shipman, Lauren

AU - Ilowite, Norman Todd

AU - Beukelman, Timothy

PY - 2017/6/19

Y1 - 2017/6/19

N2 - Background: Methotrexate is the most commonly used disease modifying antirheumatic drug in the treatment of juvenile idiopathic arthritis and can be effective in controlling disease in many patients. Main body: A significant proportion of patients experience nausea and vomiting induced by methotrexate therapy, which can lead to decreased quality of life and discontinuation of treatment with methotrexate. Many strategies have been employed in attempts to reduce methotrexate-induced nausea, including folate supplementation, switching from oral to subcutaneous methotrexate, anti-emetic therapy, behavioral therapy, and others. Anticipatory nausea can be difficult to treat, making primary prevention of nausea with anti-emetics an attractive approach. Conclusion: Understanding the prevalence and impact of methotrexate-induced nausea, as well as potentially effective interventions, may help maximize the therapeutic benefits of methotrexate.

AB - Background: Methotrexate is the most commonly used disease modifying antirheumatic drug in the treatment of juvenile idiopathic arthritis and can be effective in controlling disease in many patients. Main body: A significant proportion of patients experience nausea and vomiting induced by methotrexate therapy, which can lead to decreased quality of life and discontinuation of treatment with methotrexate. Many strategies have been employed in attempts to reduce methotrexate-induced nausea, including folate supplementation, switching from oral to subcutaneous methotrexate, anti-emetic therapy, behavioral therapy, and others. Anticipatory nausea can be difficult to treat, making primary prevention of nausea with anti-emetics an attractive approach. Conclusion: Understanding the prevalence and impact of methotrexate-induced nausea, as well as potentially effective interventions, may help maximize the therapeutic benefits of methotrexate.

KW - JIA

KW - Juvenile idiopathic arthritis

KW - Methotrexate

KW - MTX

KW - Nausea

KW - Vomiting

UR - http://www.scopus.com/inward/record.url?scp=85020890976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020890976&partnerID=8YFLogxK

U2 - 10.1186/s12969-017-0180-2

DO - 10.1186/s12969-017-0180-2

M3 - Article

VL - 15

JO - Pediatric Rheumatology

JF - Pediatric Rheumatology

SN - 1546-0096

IS - 1

M1 - 52

ER -